peptides
5-Amino-1MQ 10mg
5-Amino-1MQ is a nicotinamide N-methyltransferase (NNMT) inhibitor researched for fat mass reduction, NAD+ preservation, and improved metabolic flexibility in preclinical models.
Research-observed benefits
- ›NNMT inhibition
- ›NAD+ preservation
- ›Fat mass reduction
- ›Metabolic flexibility
Findings reported in in-vitro / preclinical research literature. Not therapeutic claims.
Reconstitution helper
Suggested: 2 mL BAC water → 5.00 mg/mL
CAS Number
—
Purity
—
Molecular Formula
—
Stock
200 units
Order type
Quantity
Research-use pricing is provided by request. with the compound name and quantity, or call 714-856-4341 for a written quote.
For in-vitro research only. Not for human consumption, diagnostic, or therapeutic use. Storage at -20°C recommended for lyophilized peptides.
5-Amino-1MQ 10mg — Full Research Breakdown
Tailored information for researchers. All content is for in-vitro / preclinical research context only — not medical advice.
Mechanism of Action
Small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor. Blocking NNMT increases intracellular NAD+ levels and S-adenosylmethionine (SAM), shifting cellular metabolism toward energy expenditure and away from fat storage.
How It Helps
Research models show reduced white adipose tissue mass, improved glucose tolerance, and increased energy expenditure — with particular interest in age-related metabolic decline and obesity models.
Half-Life
Plasma half-life in rodent models ~4–6 hours; metabolic effects persist 24+ hours.
Onset of Effects
Adipose and metabolic shifts within 2–4 weeks; body composition changes over 8–12 weeks.
Administration
Subcutaneous injection or oral gavage in published research; subcutaneous is the common research route.
Storage
Lyophilized: –20°C, protect from light. Reconstituted: refrigerate 2–8°C, use within 28 days.
Reconstitution Guide
10 mg vial + 2 mL BAC → 5 mg/mL. Dosing is typically weight-based and requires a calibrated milligram scale for oral research.
Precise Dosing Protocols
Metabolic research
- Dose:
- 1–2 mg/kg/day
- Frequency:
- Daily SC or oral
- Duration:
- 8–12 weeks
- Notes:
- Body-weight dependent; dose is often recalculated weekly
Lower-dose metabolic support
- Dose:
- 0.5–1 mg/kg/day
- Frequency:
- Daily
- Duration:
- 12 weeks
Stacks Well With
- ›MOTS-c (mitochondrial activation)
- ›NAD+ (NAD+ repletion synergy)
- ›Tesamorelin (visceral fat reduction)
Research-Observed Side Effects
- •Mild injection-site reaction
- •Transient nausea at higher doses
- •Occasional flushing
Translational Cautions
- •Pregnancy or active reproductive research
- •Active malignancy in translational models
Cycling Guidance
8–12 weeks on, 4–6 weeks off to reassess metabolic markers.
Research Highlights
- ▸Neelakantan et al. (2018): NNMT inhibition with 5-amino-1MQ reduced fat mass and improved glucose tolerance in diet-induced obesity models.
- ▸Increased NAD+ and SAM levels linked to improved mitochondrial function.
- ▸Interest in sarcopenia and metabolic syndrome research.